EGFR and neoplasm: Hsu et al. [56] recently demonstrated in patients with metastasic CRC with wild-type KRAS exon 2, who had received cetuximab (anti-EGFR) and then bevacizumab (anti-VEGF), and standard chemotherapy, an increased overall survival by reductions in microvasculature density and tumor metastasis.